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ABSTRACT
The aim of this study has been to study whether the top-down method, based on the average value 
identified in the Brazilian Hospitalization System (SIH/SUS), is a good estimator of the cost of 
health professionals per patient, using the bottom-up method for comparison. The study has been 
developed from the context of hospital care offered to the patient carrier of glucose-6-phosphate 
dehydrogenase (G6PD) deficiency with severe adverse effect because of the use of primaquine, in 
the Brazilian Amazon. The top-down method based on the spending with SIH/SUS professional 
services, as a proxy for this cost, corresponded to R$60.71, and the bottom-up, based on the 
salaries of the physician (R$30.43), nurse (R$16.33), and nursing technician (R$5.93), estimated a 
total cost of R$52.68. The difference was only R$8.03, which shows that the amounts paid by the 
Hospital Inpatient Authorization (AIH) are estimates close to those obtained by the bottom-up 
technique for the professionals directly involved in the care. 
DESCRIPTORS: Glucose-6-phosphate dehydrogenase deficiency, economics. Primaquine, adverse 
effects. Malaria, prevention & control. Health Care Costs. Unified Health System, economics. 
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INTRODUCTION 
Primaquine, an 8-aminoquinoline, is currently the only drug licensed in Brazil for the radical 
treatment of Plasmodium vivax malaria. It contributes to avoid relapses in this type of malaria 
and, consequently, decreases the number of persons with this parasite. However, this medication 
has been associated with severe hemolysis, hospitalization, and even death of male individuals 
with glucose-6-phosphate dehydrogenase (G6PD) deficiency, being the main threat to persons 
with G6PD deficiency in Brazil1,2. In the Brazilian Amazon, the estimated prevalence of G6PD 
deficiency is 4.5%3. Estimates presented by Peixoto et al.2 indicate that G6PD deficiency in 
the field of malaria is costly for the Brazilian Unified Health System (SUS), especially from 
the hospitalization costs of patients with severe adverse events associated with the use of 
primaquine. In this context, the cost-effectiveness analysis presented by Peixoto et al.4 shows that 
the use of the CareStartTM G6PD rapid diagnostic test before the administration of primaquine 
is efficient to diagnose G6PD deficiency and to avoid hospitalization in the Brazilian Amazon. 
The validity of economic evaluations depends, largely, on the method and accuracy of the 
costs evaluated5. Costs can be obtained from the detailing of items and resources used 
(bottom-up), from global estimates (top-down), or from mixed approaches that use both 
bottom-up and top-down. An approach based on top-down may be more adequate when 
the variability of a given region needs to be represented, increasing the external validity of 
the evaluation; on the other hand, bottom-up reflects the characteristics of a sample, which 
limits the generalization, despite being more precise6. 
In Brazil, the Hospitalization System (SIH/SUS) provides the values of hospitalizations 
paid by the SUS to health institutions, which subsidizes the overall costs according to the 
cause of hospitalization and contemplates hospital and professional services. Because of 
the debate on the underfunding related to the amounts paid by the SUS, the development 
of bottom-up methodologies in order to estimate hospital costs could contribute to more 
accurate economic analyses. 
The purpose of this study was to identify whether the top-down method for professional 
services, based on the average value paid for these services identified in the SIH/SUS, is a 
good estimator of the cost of health professionals. This was carried out in relation to the 
bottom-up method based on the salaries of the physician, nurse, and nursing technician 
in the context of hospital care given to the male patient with G6PD deficiency with severe 
adverse event from the use of primaquine in the Brazilian Amazon. 
METHODS 
A comparison of costing methods was carried out in the context of an economic analysis 
developed from the perspective of the SUS for 2013, considering all nine States of the Brazilian 
Amazon. We analyzed the cost of professional service with the hospitalization of patients with 
G6PD deficiency submitted to the radical treatment of P. vivax infection with primaquine. 
To obtain this cost, we used two techniques: the top-down, performed from an administrative 
database based on the Professional Service component of the Hospitalization Authorization 
(AIH) paid by SUS, and the bottom-up, based on the casuistry of the Fundação de Medicina 
Tropical Dr. Heitor Vieira Dourado (FMT-HVD), a center of reference in malaria care and 
research in the State of Amazonas, fully funded by the SUS, located in the city of Manaus. 
The top-down technique obtained the average value of the Professional Service component 
of the AIH from the analysis of the SIH/SUS databases, using the following procedure: the 108 
files that contain the SIH/SUS registry data from the nine States of the Brazilian Amazon, 
of 2013, were obtained in the *.dbf format and exported to the Statistical Package for the 
Social Sciences (SPSS®) software, version 20.0, being transformed into the *.sav format; 
the databases were analyzed individually in the SPSS®. Using the localization function of 
the SPSS®, we identified the male individuals older than six months hospitalized for the 
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treatment of hemolytic anemia from G6PD deficiency (ICD-10 D550). Subsequently, the 
results of the analyses were grouped into a single file, allowing us to obtain the average value 
of said component. Although the professional service component of the AIH refers mainly 
to the costs of the physician’s service, this component was also used as a proxy for the total 
professional costs (physician, nurse, and nursing technician), since we cannot discriminate 
the cost of the service of other professionals from the hospital service component of the AIH. 
The bottom-up technique was based on the average salaries practiced by the State of Amazonas 
in 2013, for the physician, nurse, and nursing technician (total professional cost), which 
allowed us to compare the total professional cost, physician cost, and the value obtained from 
the analysis of the professional service component of the AIH. From the monthly salary, we 
identified the value of one hour of work (monthly salary divided by the monthly work hours), 
followed by its multiplication by the estimated hours dedicated to the patient, which was 
obtained by multiplying the average number of days of hospitalization (4.58 days) and 24 hours. 
This product was then weighted by the proportion of patients hospitalized for G6PD deficiency 
at the FMT-HVD, since health professionals do not exclusively treat patients hospitalized for 
G6PD deficiency (Table). The average number of days hospitalized and the number of patients 
hospitalized for G6PD deficiency who subsidized the calculation of the proportion of inpatients 
were obtained from unpublished information from the monitoring of 33 males with G6PD 
deficiency, and mean age of 24.3 years, hospitalized at FMT-HVD between 2009 and 2011 for 
the adverse events of primaquine. Thus, the proportion of inpatients with G6PD deficiency 
was calculated based on the division between the 33 hospitalizations of patients with enzyme 
deficiency and the 8,654 hospitalizations from all causes in the institution in the same period 
(amounting to 0.38%).
Univariate sensitivity analyses were performed based on the 95% confidence intervals 
(95%CI) of the following parameters: proportion of hospitalization from G6PD deficiency 
and average days of hospitalization. 
RESULTS 
The average cost of professional services obtained by the top-down technique, based on the 
analysis of hospitalizations identified in the SIH/SUS, corresponded to R$60.71. The bottom-up, 
based on the salaries of the physician, nurse, and nursing technician, indicated a cost of R$52.68, 
with a preponderance of the cost with the physician (R$30.43), followed by the nurse (R$16.33), 
and the nursing technician (R$5.93). We can observe that the difference between the costs 
obtained from the different techniques, considering the total professional cost, was only R$8.03, 
and considering only the physician costs it was R$30.28 (Table). The univariate sensitivity analysis 
Table. Estimation of the cost of professional services involved in the hospitalization of a patient carrier of G6PD deficiency infected by P. 
vivax after the use of primaquine in the Brazilian Amazon, 2013.
Professionals
(A) (B) (C) (D) (E1) Análise de sensibilidade
Monthly 
Salary (R$)
Work hours 
per week
Work hours 
per month
Value of the 
hours worked
Professional cost 
per patient (E2) (E3)
C = B*4 (A/C) E = D*4.58a*24h*0.38%b
Proportion of 
inpatients
(0.25%–0.51%)c
Average days of 
hospitalization
(2.58–6.57)d
Physician 5,832.98 20 80 72.91 30.43 20.02–40.84 17.16–43.69
Nurse 4,694.41 30 120 39.12 16.33 10.74–21.91 9.20–23.44
Nursing technician 1,704.1 30 120 14.21 5.93 3.90–7.95 3.34–8.51
Total 52.68 34.66–70.70 29.70–75.64
Difference between costs: top-down versus bottom-up
Difference 1e 30.28 19.87–40.69 17.02–43.55
Difference 2f 8.03 -9.99–26.05 -14.93–31.01
a Average days of hospitalization for G6PD deficiency at FMT-HVD. 
b Proportion of hospitalization for G6PD deficiency among the inpatients at FMT-HVD. 
c Variation of the professional cost per patient based on the confidence interval (95%CI) of the proportion of inpatients for G6PD deficiency among the inpatients 
at FMT-HVD.
d Variation of the professional cost per patient based on the confidence interval (95%CI) of the average days of hospitalization for G6PD deficiency at FMT-HVD. 
e Difference between top-down (R$60.71) and bottom-up based only on the physician cost.
f Difference between top-down (R$60.71) and bottom-up based on the total professional cost (physician, nurse, and nursing technician).
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performed with the proportion of hospitalization and the average number of days hospitalized for 
G6PD deficiency showed that the total professional cost obtained using the bottom-up method 
ranged between R$34.66 and R$70.70 and between R$29.70 and R$75.64 (Table), respectively. 
DISCUSSION 
The hospital costs obtained from the analysis of the regional and national registries of the 
SIH/SUS have subsidized several economic analyses developed from the SUS perspective, thus 
enabling, according to Silva et al.7, a more comprehensive view. According to the guidelines for 
the economic evaluation proposed by the Ministry of Health (MS), the hospitalization costs 
obtained from the AIH values have been used in almost all studies conducted in Brazil, although 
the AIH is criticized for representing the values reimbursed and not necessarily the actual costs6. 
In this context, we can observe the use of the average value of the AIH, which was obtained 
from the analysis of the SIH/SUS, in studies with the most varied objectives, such as: disease 
cost assessment2,8, analysis of vaccine efficacy9,10, efficiency of new diagnostic technologies4, 
efficiency of programs11, and efficiency of new therapeutic technologies12, among others. 
The discussion about the devaluation of the amounts paid by the AIH should also be 
considered in economic analyses. In this regard, Sampaio et al.13, when studying the financial 
management of neurosurgery, have compared the amounts paid by the AIH with the expenses 
cataloged by patients during the period from August 2012 to June 2013. The authors13 have 
identified a deficit of R$395,329.17 between the amounts obtained by the bottom-up technique 
(R$718,036.70) and the amount reimbursed by the AIH (R$321,607.45). Lucarevschi et al.14, 
when combining the bottom-up and top-down techniques to assess direct hospital costs 
related to pneumococcal meningitis in children, have identified costs 10 to 20 times higher 
than those paid by the AIH. Given the variety of health outcomes, we can assume that the 
amount paid by the AIH may also overestimate the cost of hospitalization for some outcomes, 
although this study has not identified publications that support this assumption. 
In this study, the bottom-up value of professional services, initially considering only the cost 
of the physician, compared to the top-down, presented value corresponding to half of the 
amount reimbursed by the AIH. However, when simultaneously considered the costs of the 
physician, the nurse, and the nursing technician, the value obtained was very close to the 
top-down value, indicating that the AIH can be a good proxy of the estimation of costs of 
services of the professionals directly involved in the care of persons with G6PD deficiency 
when compared with the bottom-up technique. 
This study presents some limitations, such as the fact that some epidemiological parameters 
and the costs used in the bottom-up technique come from the casuistry of the State of 
Amazonas and they are extrapolated to the entire Brazilian Amazon. The uncertainties 
considered in the univariate sensitivity analysis indicated that the professional costs did not 
show significant variations, although they were influenced by the variation of the proportion 
of hospitalized patients for G6PD deficiency and days of hospitalization. 
The comparison between the bottom-up and top-down methods is an unprecedented contribution 
to the discussion of costing techniques for professional costs in malaria care settings in the 
Brazilian Amazon, with the potential to support future economic studies in the area. It should be 
noted that the AIH is widely used in Brazil as a source of hospital care costs, as it facilitates the 
comparison between economic studies and represents the values practiced in the service routine. 
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